This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Does Lilly's New Obesity Pill Data Put It Back in the Weight Game?
by Kinjel Shah
LLY's obesity pill orforglipron hits weight-loss and A1C goals in a phase III trial, lifting shares nearly 6% and reviving investor confidence.
AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing headwinds pose challenges.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?
by Kinjel Shah
Johnson & Johnson stock surges above key moving averages as strong results, raised guidance and growth prospects fuel momentum.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Is Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?
by Kinjel Shah
Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes alive.
Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?
by Kinjel Shah
J&J battles Stelara losses, talc lawsuits, tariffs and China headwinds while banking on growth plans and new launches to stay resilient.
Lilly Stock Down 5% This Month: Should You Buy the Dip?
by Kinjel Shah
Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill orforglipron disappointed.
SNY's Rilzabrutinib Gets EU Orphan Drug Tag for IgG4-Related Disease
by Zacks Equity Research
Sanofi wins EMA's orphan drug status for rilzabrutinib to treat IgG4-RD, a chronic, immune-mediated rare disease.
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novo Nordisk Rises 6% So Far in August: How to Play the Stock
by Ahan Chakraborty
NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's advancing pipeline.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
by Zacks Equity Research
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season
by Zacks Equity Research
AMGN posts strong Q2 results as Repatha, Evenity, Blincyto and rare disease drugs power broad-based volume gains.
LLY Stock Sinks Despite Q2 Earnings Beat as Obesity Pill Disappoints
by Zacks Equity Research
LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.
Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly
by Zacks Equity Research
Amgen posts strong Q2 beats on earnings and sales, driven by double-digit drug volume gains.
Small-Caps Stay Higher, Other Indexes Dwindle
by Mark Vickery
President Trump mentioned adding new tariffs on semiconductor imports, which helped move markets aside from the Russell 2000 lower.
Amgen (AMGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amgen (AMGN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of +14.45% and +3.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Trade Deficit Narrowed More Than Expected
by Zacks Equity Research
Trade Deficit Narrowed More Than Expected
Pre-markets Slightly Up on Mostly Good Q2 Earnings
by Mark Vickery
Q2 earnings reports are overall posting favorable results, including this morning ahead of the open.
3 Top Dividend Stocks to Maximize Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Selloff? What Selloff? Monday Market Rebound
by Mark Vickery
Palantir is way up after reporting Q2 results Monday afternoon, while HIMS and VRTX are way off highs.
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, Ozempic and Rybelsus.
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
by Zacks Equity Research
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.